Shares of Beyondspring Inc (NASDAQ:BYSI) have been assigned a consensus rating of “Buy” from the six analysts that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $37.50.
A number of equities analysts have weighed in on BYSI shares. Zacks Investment Research raised shares of Beyondspring from a “sell” rating to a “hold” rating in a research note on Monday, January 6th. William Blair reaffirmed a “buy” rating on shares of Beyondspring in a research note on Friday, January 10th. ValuEngine raised shares of Beyondspring from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Nomura started coverage on shares of Beyondspring in a research note on Friday, January 10th. They set a “buy” rating and a $34.00 price target on the stock.
Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in Beyondspring during the second quarter worth approximately $66,000. Nisa Investment Advisors LLC acquired a new stake in shares of Beyondspring in the third quarter worth $134,000. Barclays PLC increased its position in shares of Beyondspring by 49.0% in the third quarter. Barclays PLC now owns 10,281 shares of the company’s stock worth $186,000 after acquiring an additional 3,379 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in shares of Beyondspring in the second quarter worth $439,000. Finally, California State Teachers Retirement System increased its position in shares of Beyondspring by 13.3% in the third quarter. California State Teachers Retirement System now owns 18,686 shares of the company’s stock worth $338,000 after acquiring an additional 2,200 shares in the last quarter. 5.66% of the stock is currently owned by institutional investors.
Beyondspring stock traded up $0.31 during trading on Friday, reaching $17.96. The company had a trading volume of 113,100 shares, compared to its average volume of 69,025. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.61 and a current ratio of 3.61. The firm has a market capitalization of $458.27 million, a price-to-earnings ratio of -7.42 and a beta of 1.31. Beyondspring has a 12-month low of $11.26 and a 12-month high of $24.80. The stock’s 50 day moving average price is $15.27 and its two-hundred day moving average price is $16.44.
Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings results on Wednesday, December 18th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.07). As a group, research analysts expect that Beyondspring will post -1.47 earnings per share for the current year.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Further Reading: Diversification in Your Portfolio
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.